Brain cancer hope: new drug combo shows promise in early trial
NCT ID NCT04959500
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the drug anlotinib hydrochloride to the standard Stupp regimen (chemoradiation) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 150 adults aged 18-75 with this aggressive brain tumor are participating. The trial is double-blind, meaning neither patients nor doctors know who gets the extra drug, to ensure fair results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anlotinib hydrochloride
What this could lead to
If successful, this could offer a new treatment option that slows the growth of glioblastoma, a fast-growing brain cancer.
What could go wrong
This is an early phase 2 trial with only 150 participants, so results may not apply to all patients. The drug also has side effects like high blood pressure and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing TianTan Hospital,Capital Medical University
Beijing, Beijing Municipality, 100070, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China
-
Fudan University shabghai cancer center
Shanghai, Shanghai Municipality, 200433, China
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Gansu Provincial Hospital
Gansu, Lanzhou Province, 730000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Lanzhou University Second Hospital
Lanzhou, Gansu, 730000, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110042, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, 518000, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Fifth Affiliated Hospital Sun Yat-sen University
Zhuhai, Guangdong, 519000, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004, China
-
The First Affiliated Hospital of NanChang University
Nanchang, Jiangxi, 330006, China
-
The First Hospital of Lanzhou University
Lanzhou, Gansu, 730000, China
-
The General Hospital of the People's Liberation Army (PLAGH)
Beijing, Beijing Municipality, 100853, China
-
The Second Affiliated Hospital of PLA Air Force Medical University
Xian, Shanxi, 710000, China
-
The Sixth Madical Center of PLA General Hospital
Beijing, Beijing Municipality, 100142, China
-
The affiliated hospital of xuzhou medical university
Xuzhou, Jiangsu, 221000, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000, China